Effect of Coenzyme Q10 as an adjunct therapy versus placebo on para-clinical signs after primary angioplasty of coronary artery in acute ST-elevation myocardial infarction

Effect of Coenzyme Q10 as an adjunct therapy versus placebo on para-clinical signs after primary angioplasty of coronary artery in acute ST-elevation myocardial infarction: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N407

Enrollment

Registered

2021-11-18

Start date

2021-12-06

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST elevation myocardial infarction. ST elevation (STEMI) myocardial infarction of anterior wall

Interventions

Intervention 1: Intervention group: Routine treatment plus injection of Coenzyme Q10 400 mg (manufactured by Dana pharmaceutical Co.) immediately after angioplasty and then 200 mg every 12 hours for 2

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 80 years; Myocardial ischemia for at least 30 minutes; Myocardial infarction disease in the last 12 hours; Elevated ST segment on electrocardiogram; Angioplasty for the first time;

Exclusion criteria

Exclusion criteria: Candidate for emergency coronary bypass surgery; History of heart attack or heart failure or angioplasty; Indication for thrombolytic therapy; Cardiogenic shock; Liver failure; Autoimmune diseases or inflammation; Taking antioxidant medicines in the past month;

Design outcomes

Primary

Measure	Time frame
The serum level of troponin. Timepoint: Before angioplasty and 6, 12, 24, 48, and 72 hours after that. Method of measurement: By laboratory test.;The serum level of CK-MB. Timepoint: Before angioplasty and 6, 12, 24, 48, and 72 hours after that. Method of measurement: By laboratory test.;Thrombolysis in myocardial infarction (TIMI) flow grade. Timepoint: After angioplasty. Method of measurement: By laboratory test.;Myocardial blushing grade (MBG). Timepoint: After angioplasty. Method of measurement: By echocardiography.;ST-segment resolution. Timepoint: Immediately and 24 hours after angioplasty. Method of measurement: By echocardiography.;Left ventricular ejection fraction. Timepoint: 30 days after angioplasty. Method of measurement: By echocardiography.	—

Measure

Time frame

The serum level of troponin. Timepoint: Before angioplasty and 6, 12, 24, 48, and 72 hours after that. Method of measurement: By laboratory test.;The serum level of CK-MB. Timepoint: Before angioplasty and 6, 12, 24, 48, and 72 hours after that. Method of measurement: By laboratory test.;Thrombolysis in myocardial infarction (TIMI) flow grade. Timepoint: After angioplasty. Method of measurement: By laboratory test.;Myocardial blushing grade (MBG). Timepoint: After angioplasty. Method of measurement: By echocardiography.;ST-segment resolution. Timepoint: Immediately and 24 hours after angioplasty. Method of measurement: By echocardiography.;Left ventricular ejection fraction. Timepoint: 30 days after angioplasty. Method of measurement: By echocardiography.

—

Secondary

Measure	Time frame
Adverse effects (heart failure, cardiogenic shock, re-infarction, and death). Timepoint: during the treatment period. Method of measurement: with taking history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKimia Shirmohammadi

Hamedan University of Medical Sciences

kimiashirmohamadi99@gamil.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026